Birnbaum B A, Weinreb J C, Fernandez M P, Brown J J, Rofsky N M, Young S W
Department of Radiology, New York University Medical Center, New York 10016.
Clin Imaging. 1994 Jan-Mar;18(1):21-7. doi: 10.1016/0899-7071(94)90141-4.
Twenty-nine patients with known or suspected focal hepatic disease were evaluated in a retrospective multi-institutional study comparing T1-weighted manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis (phosphate) (DPDP) enhanced magnetic resonance imaging (MRI) with dynamic sequential bolus contrast enhanced computed tomography (DBCT) for the detection of focal liver lesions. The patients were divided into four dose groups, receiving 3, 5, 8, or 10 mumol/kg of Mn-DPDP, delivered either via intravenous bolus (0.25 ml/sec) or infusion (1 ml/sec). Each of three readers, with varying levels of expertise in interpreting hepatic MRI and CT studies, identified more lesions on the Mn-DPDP enhanced MRI than the contrast enhanced CT images. Mn-DPDP enhanced MRI depicted the presence of extensive metastatic disease not seen with DBCT in three patients with fatty liver. The most experienced MRI reader saw more lesions per patient on the Mn-DPDP enhanced MRI than with DBCT, while the opposite held true for the most experienced CT reader. The best single exam for detection of hepatic lesions may be determined by the experience of the reader.
在一项回顾性多机构研究中，对29例已知或疑似局灶性肝病患者进行了评估，该研究比较了T1加权锰（II）N，N'-二吡啶氧基乙二胺-N，N'-二乙酸5,5'-双（磷酸盐）（DPDP）增强磁共振成像（MRI）与动态序贯团注对比增强计算机断层扫描（DBCT）用于检测肝脏局灶性病变。患者被分为四个剂量组，分别接受3、5、8或10 μmol/kg的锰-二吡啶二乙酸酯（Mn-DPDP），通过静脉推注（0.25 ml/秒）或输注（1 ml/秒）给药。三位对肝脏MRI和CT研究解读专业水平不同的阅片者，在Mn-DPDP增强MRI上识别出的病变均多于对比增强CT图像。Mn-DPDP增强MRI显示，在3例脂肪肝患者中存在DBCT未发现的广泛转移性疾病。经验最丰富的MRI阅片者在Mn-DPDP增强MRI上看到的每位患者病变比DBCT更多，而经验最丰富的CT阅片者情况则相反。检测肝脏病变的最佳单项检查可能取决于阅片者的经验。
